AZN
PUTS ▼AstraZeneca PLC
$169.64
-0.99%delayed
News – · Trend ▼ · below put trigger ▼
Expected move (1d)
▼ $165.27to$174.01 ▲
ATR ±$4.37 (+2.58%)Implied ±$8.45 (+4.98%)
Entry Reference
Price / prev close$169.64 / $171.34
Day range$168.44 – $170.72
52-wk range$145.80 – $212.71(36%)
Volume vs avg0.70×
ATR (14d)$4.37
MA 8 / 21$170.46 / $174.09
MA 50 / 200$179.16 / $184.80
Call ▲ / Put ▼ trigger$172.37 / $170.31
+1 / +2 ATR$174.01 / $178.39
-1 / -2 ATR$165.27 / $160.89
Support: 164.06
Resistance: 173.66 174.60 180.00
Near-the-money contracts
exp 2026-08-21Calls
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 155 | $15.40 | 41% | 0.85 | -0.11 | 5 |
| 160 | $11.00 | 36% | 0.78 | -0.12 | 38 |
| 165 | $6.65 | 28% | 0.69 | -0.11 | 248 |
| 170 | $3.85 | 27% | 0.51 | -0.12 | 1803 |
| 175 | $1.98 | 26% | 0.33 | -0.10 | 949 |
| 180 | $1.00 | 27% | 0.19 | -0.08 | 865 |
Puts
| Strike | Mark | IV | Δ | θ/day | OI |
|---|---|---|---|---|---|
| 155 | $0.68 | 34% | -0.11 | -0.06 | 243 |
| 160 | $1.78 | 39% | -0.23 | -0.11 | 215 |
| 165 | $2.47 | 30% | -0.32 | -0.10 | 588 |
| 170 | $4.60 | 30% | -0.48 | -0.11 | 371 |
| 175 | $7.70 | 31% | -0.64 | -0.10 | 194 |
| 180 | $11.60 | 35% | -0.75 | -0.09 | 177 |
Δ = delta (≈ probability ITM), θ/day = daily time decay, IV = implied vol. Greeks computed via Black-Scholes from Yahoo IV.
Recent news
- Low Growth Viatris Is Due For A Pullback After A Stellar 16-Month Run1d ago
- EU Approves Daiichi Sankyo And AstraZeneca's Datroway For First-Line Metastatic TNBC, Showing 5.0 Month Overall Survival Improvement Over Chemotherapy In TROPION-Breast02 Trial2d ago
- Alnylam Lowers 2026 Outlook As Second-Line Amvuttra Demand Normalizes, Stock Tanks2d ago
- Oakmark Global All Cap Strategy Q2 2026 Portfolio Performance4d ago
- Dow Gains Over 250 Points Amid Lower Oil Prices: Investor Sentiment Weakens, Greed Index Remains In ‘Fear’ Zone5d ago
- AstraZeneca PLC (AZN) Q2 2026 Earnings Call Transcript5d ago
- AstraZeneca: Q2 2026 Results Were All Right, But Farxiga Poses Risks5d ago
- Dow Jumps Over 400 Points; AstraZeneca Shares Rise After Q2 Earnings6d ago
- Pipeline Speed Bump Doesn't Shake AstraZeneca's $80 Billion Revenue Ambition6d ago
- AstraZeneca Announces That Results From Its CLARITY-Gastric01 Global Phase III Trial Showed That Sonesitatug Vedotin Demonstrated Statistically Significant And Highly Clinically Meaningful Improvement In Overall Survival6d ago
- AstraZeneca PLC 2026 Q2 - Results - Earnings Call Presentation6d ago
- AstraZeneca Q2 Adj. EPS $2.63 Beats $2.48 Estimate, Sales $15.384B Miss $15.459B Estimate6d ago
Reference data only. Not a recommendation. Greeks and expected-move figures are estimates, not certainties. You confirm all entries and contracts in TradingView and Charles Schwab.